BMYBristol-Myers SquibbNot started yet
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Early-Stage Non-Small Cell Lung Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 80 (planned)
- Started
- Nov 30, 2026
- Main results expected
- Mar 15, 2028
- Fully finished
- Mar 15, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Achievement of pathologic complete response (pCR) by blinded independent pathology review (BIPR)
Measured over: Up to 6 weeks after last dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07871214 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC